Generic Name: pembrolizumab
Brand Name: Keytruda
Manufacturer: Merck Canada Inc.
Therapeutic Area: Colorectal cancer
Indications: For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
Manufacturer Requested Reimbursement Criteria1: For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)
Submission Type: Initial
NOC Status at Filing: Pre NOC
Project Status: Active
Companion Diagnostics: Yes
Fee Schedule1: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 |
|
|---|---|
| Call for patient/clinician input open | November 02, 2020 |
| Call for patient/clinician input closed | December 24, 2020 |
| Clarification:
- Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network |
|
| Submission received | November 30, 2020 |
| Submission accepted | December 14, 2020 |
| Review initiated | December 15, 2020 |
| Draft CADTH review report(s) provided to sponsor for comment | March 08, 2021 |
| Deadline for sponsors comments | March 17, 2021 |
| CADTH responses on draft review report(s) provided to sponsor | May 03, 2021 |
| Expert committee meeting (initial) | May 14, 2021 |
| Draft recommendation issued to sponsor | May 31, 2021 |
| Draft recommendation posted for stakeholder feedback | June 10, 2021 |
| End of feedback period | June 24, 2021 |